At the end of the day, weight loss options, like any other health-related decisions, are very personal and must be made on a ...

While some orthopedic and spine surgeons are divided on how medications used for weight loss, including Ozempic and Wegovy, will shape the field, it is undeniable that the drugs are playing an ...

Experts noted that rapid and extreme weight loss can introduce unique risks, such as a weakened immune system and malnourishment, as well as potentially too much muscle loss. They’re also concerned ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Pursuing the world's first-ever orally-dosed liraglutide KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global ...

One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...

GLP-1 receptor agonists, initially developed for type 2 diabetes treatment, work by mimicking a naturally occurring gut ...

As India awaits the launch of obesity drug, Mounjaro, the debate on weight loss drugs and body image continues ...

Discover how Medifast navigates GLP-1 market shifts with innovative products like OPTAVIA ASCEND, cost-saving initiatives, and growth strategies for 2025.

A doctor emphasized that ozempic, a lab-engineered drug, effectively activates GLP-1 receptors for weight loss, unlike foods ...